Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Tracon Pharmaceuticals Stock Quote

Tracon Pharmaceuticals (NASDAQ: TCON)

$1.87
(2.7%)
$0.05
Price as of April 23, 2024, 3:00 p.m. ET

Tracon Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
TCON -94.89% -98.61% -57.50% -100%
S&P +21.22% +71.17% +11.35% +151%

Tracon Pharmaceuticals Company Info

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.